Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax (Euronext/Nasdaq: ABVX) will hold its Annual Ordinary and Extraordinary General Meeting on May 11, 2026 at 3:00 pm CEST in Paris (Paris Marriott Opera Ambassador).

Rhea-AI Summary

Abivax (Euronext/Nasdaq: ABVX) will hold its Annual Ordinary and Extraordinary General Meeting on May 11, 2026 at 3:00 pm CEST in Paris (Paris Marriott Opera Ambassador).

Preparatory documents, agenda and draft resolutions are available to shareholders on the company website and were published in BALO on April 3, 2026 (N°2600756).

Argus Apr 21 session

-3.09% close to close Open Argus

Details

News Market Reaction – ABVX

In the Apr 21 session, ABVX declined 3.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the framework for Abivax’s ordinary and extraordinary general meeting on May ...

Analysis

This announcement sets the framework for Abivax’s ordinary and extraordinary general meeting on May 11, 2026, detailing the venue, time, agenda publication in BALO, and access to preparatory documents under Article R.22-10-23 of the French Commercial Code. It is primarily procedural, but investors should review the draft resolutions once available, focusing on any proposed changes to capital structure, governance, or strategic authorizations that could influence future corporate flexibility.

Key Figures

General Meeting date: May 11, 2026 Meeting time: 3:00 pm (CEST) Publication time: 10:05 PM CEST +4 more

General Meeting date

May 11, 2026

Scheduled date of ordinary and extraordinary general meeting

Meeting time

3:00 pm (CEST)

Scheduled time of the General Meeting

Publication time

10:05 PM CEST

Time of press release on April 20, 2026

BALO notice date

April 3, 2026

Date of preliminary meeting notice in BALO

BALO notice number

N°2600756

Reference number of the BALO publication

Street address

16 boulevard Haussmann

Location of Paris Marriott Opera Ambassador hotel for meeting

Postal code

75009

Postal code of meeting venue in Paris

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   Regulatory filings posted

   24h Move

   +3.0%

   Publication of Universal Registration Document and Form 20-F annual report.

2. Mar 23

   Full-year 2025 results

   24h Move

   -4.5%

   Reported large 2025 net loss alongside business updates and cash runway detail.

3. Feb 21

   Clinical data at ECCO

   24h Move

   +2.0%

   Presented 22 abstracts with anti-fibrotic evidence and supportive IBD efficacy data.

4. Jan 07

   2026 corporate outlook

   24h Move

   -8.7%

   Outlined obefazimod plans, growing UC market projections and cash runway into Q4 2027.

5. Dec 18

   Index inclusion

   24h Move

   +1.2%

   Announcement of inclusion in Nasdaq Biotechnology Index following Phase 3 progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

general meeting, french commercial code

2 terms

general meeting regulatory

"informs its shareholders that its ordinary and extraordinary general meeting"

A general meeting is a formal gathering of a company’s shareholders where key decisions are discussed and voted on, similar to a town-hall where owners set rules for the business. Investors attend or vote remotely to approve matters such as board members, dividend policies, mergers or major changes, making it a direct way to influence management and protect or change the company’s direction. Outcomes can affect the company’s strategy, governance and share value.

french commercial code regulatory

"The documents referred to in Article R.22-10-23 of the French Commercial Code"

The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026
Availability of the Preparatory Documents

PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com

About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Attachment

• 260420_Abivax_PR_AGM Preparatory Documents

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where is Abivax's (ABVX) Annual Ordinary and Extraordinary General Meeting on May 11, 2026?

The meeting is scheduled for May 11, 2026 at 3:00 pm CEST in Paris. According to Abivax, it will take place at the Paris Marriott Opera Ambassador, 16 boulevard Haussmann, and is open to shareholders following notice procedures.

How can ABVX shareholders access the preparatory documents for the May 11, 2026 General Meeting?

Shareholders can access documents on the company's website. According to Abivax, the documents referred to in Article R.22-10-23 of the French Commercial Code are available at www.abivax.com.

What was published in BALO regarding Abivax (ABVX) before the May 11, 2026 General Meeting?

A preliminary notice of meeting with the agenda and draft resolutions was published in BALO on April 3, 2026 (N°2600756). According to Abivax, this notice informs shareholders how to attend and vote.

How do ABVX shareholders vote at the May 11, 2026 General Meeting if they cannot attend in person?

Shareholders may vote remotely or by proxy following legal procedures. According to Abivax, instructions on how to attend and vote remotely are included in the preparatory documents available on the company website.

What topics will be covered at Abivax's (ABVX) Annual Ordinary and Extraordinary General Meeting on May 11, 2026?

The agenda includes ordinary and extraordinary resolutions for shareholder approval. According to Abivax, the preliminary notice and draft resolutions set out the specific items to be voted on at the meeting.